| pubmed-article:20512334 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:20512334 | lifeskim:mentions | umls-concept:C0006142 | lld:lifeskim |
| pubmed-article:20512334 | lifeskim:mentions | umls-concept:C1516213 | lld:lifeskim |
| pubmed-article:20512334 | lifeskim:mentions | umls-concept:C0008976 | lld:lifeskim |
| pubmed-article:20512334 | lifeskim:mentions | umls-concept:C0144576 | lld:lifeskim |
| pubmed-article:20512334 | lifeskim:mentions | umls-concept:C0282564 | lld:lifeskim |
| pubmed-article:20512334 | lifeskim:mentions | umls-concept:C0574032 | lld:lifeskim |
| pubmed-article:20512334 | lifeskim:mentions | umls-concept:C0045093 | lld:lifeskim |
| pubmed-article:20512334 | lifeskim:mentions | umls-concept:C0205390 | lld:lifeskim |
| pubmed-article:20512334 | lifeskim:mentions | umls-concept:C0439590 | lld:lifeskim |
| pubmed-article:20512334 | lifeskim:mentions | umls-concept:C0086960 | lld:lifeskim |
| pubmed-article:20512334 | lifeskim:mentions | umls-concept:C0585332 | lld:lifeskim |
| pubmed-article:20512334 | lifeskim:mentions | umls-concept:C0205179 | lld:lifeskim |
| pubmed-article:20512334 | pubmed:issue | 3 | lld:pubmed |
| pubmed-article:20512334 | pubmed:dateCreated | 2011-2-22 | lld:pubmed |
| pubmed-article:20512334 | pubmed:abstractText | Paclitaxel (PACL) plus gemcitabine (GEM) is an effective regimen for advanced breast cancer patients pretreated with anthracyclines. A prolonged GEM infusion at a fixed dose rate (FDR) of 10 mg/m²/min produces higher levels of intracellular active metabolites of GEM when compared with a standard 30-min infusion. In the present phase I/II trial, we investigated the association of FDR GEM plus PACL. | lld:pubmed |
| pubmed-article:20512334 | pubmed:language | eng | lld:pubmed |
| pubmed-article:20512334 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20512334 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:20512334 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20512334 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20512334 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20512334 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20512334 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20512334 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20512334 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20512334 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:20512334 | pubmed:month | Mar | lld:pubmed |
| pubmed-article:20512334 | pubmed:issn | 1432-0843 | lld:pubmed |
| pubmed-article:20512334 | pubmed:author | pubmed-author:GiannarelliDi... | lld:pubmed |
| pubmed-article:20512334 | pubmed:author | pubmed-author:LopezMassimoM | lld:pubmed |
| pubmed-article:20512334 | pubmed:author | pubmed-author:ViciPatriziaP | lld:pubmed |
| pubmed-article:20512334 | pubmed:author | pubmed-author:Di... | lld:pubmed |
| pubmed-article:20512334 | pubmed:author | pubmed-author:BeplerGeroldG | lld:pubmed |
| pubmed-article:20512334 | pubmed:author | pubmed-author:ContiFrancesc... | lld:pubmed |
| pubmed-article:20512334 | pubmed:author | pubmed-author:CognettiFranc... | lld:pubmed |
| pubmed-article:20512334 | pubmed:author | pubmed-author:FabiAlessandr... | lld:pubmed |
| pubmed-article:20512334 | pubmed:author | pubmed-author:MetroGiulioG | lld:pubmed |
| pubmed-article:20512334 | pubmed:author | pubmed-author:TomaoFederica... | lld:pubmed |
| pubmed-article:20512334 | pubmed:author | pubmed-author:SergiDomenico... | lld:pubmed |
| pubmed-article:20512334 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:20512334 | pubmed:volume | 67 | lld:pubmed |
| pubmed-article:20512334 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:20512334 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:20512334 | pubmed:pagination | 687-93 | lld:pubmed |
| pubmed-article:20512334 | pubmed:meshHeading | pubmed-meshheading:20512334... | lld:pubmed |
| pubmed-article:20512334 | pubmed:meshHeading | pubmed-meshheading:20512334... | lld:pubmed |
| pubmed-article:20512334 | pubmed:meshHeading | pubmed-meshheading:20512334... | lld:pubmed |
| pubmed-article:20512334 | pubmed:meshHeading | pubmed-meshheading:20512334... | lld:pubmed |
| pubmed-article:20512334 | pubmed:meshHeading | pubmed-meshheading:20512334... | lld:pubmed |
| pubmed-article:20512334 | pubmed:meshHeading | pubmed-meshheading:20512334... | lld:pubmed |
| pubmed-article:20512334 | pubmed:meshHeading | pubmed-meshheading:20512334... | lld:pubmed |
| pubmed-article:20512334 | pubmed:meshHeading | pubmed-meshheading:20512334... | lld:pubmed |
| pubmed-article:20512334 | pubmed:meshHeading | pubmed-meshheading:20512334... | lld:pubmed |
| pubmed-article:20512334 | pubmed:meshHeading | pubmed-meshheading:20512334... | lld:pubmed |
| pubmed-article:20512334 | pubmed:meshHeading | pubmed-meshheading:20512334... | lld:pubmed |
| pubmed-article:20512334 | pubmed:meshHeading | pubmed-meshheading:20512334... | lld:pubmed |
| pubmed-article:20512334 | pubmed:meshHeading | pubmed-meshheading:20512334... | lld:pubmed |
| pubmed-article:20512334 | pubmed:meshHeading | pubmed-meshheading:20512334... | lld:pubmed |
| pubmed-article:20512334 | pubmed:meshHeading | pubmed-meshheading:20512334... | lld:pubmed |
| pubmed-article:20512334 | pubmed:meshHeading | pubmed-meshheading:20512334... | lld:pubmed |
| pubmed-article:20512334 | pubmed:meshHeading | pubmed-meshheading:20512334... | lld:pubmed |
| pubmed-article:20512334 | pubmed:meshHeading | pubmed-meshheading:20512334... | lld:pubmed |
| pubmed-article:20512334 | pubmed:meshHeading | pubmed-meshheading:20512334... | lld:pubmed |
| pubmed-article:20512334 | pubmed:year | 2011 | lld:pubmed |
| pubmed-article:20512334 | pubmed:articleTitle | Phase I-II trial of prolonged gemcitabine infusion plus paclitaxel as a biweekly schedule for advanced breast cancer patients pretreated with anthracyclines. | lld:pubmed |
| pubmed-article:20512334 | pubmed:affiliation | Department of Medical Oncology, Regina Elena Cancer Institute, Rome, Italy. pvici@ifo.it | lld:pubmed |
| pubmed-article:20512334 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:20512334 | pubmed:publicationType | Comparative Study | lld:pubmed |
| pubmed-article:20512334 | pubmed:publicationType | Clinical Trial, Phase II | lld:pubmed |
| pubmed-article:20512334 | pubmed:publicationType | Clinical Trial, Phase I | lld:pubmed |
